MedTrace Logo

Hepatic Resection Versus TACE+RFA for BCLC Stage B Hepatocellular Carcinoma

NCT02616926 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 538

Last updated 2015-12-07

No results posted yet for this study

Summary

Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world. For patients with intermediate HCC (BCLC stage B), transarterial chemoembolization (TACE) has been recommended as the standard therapy in many clinical practice guidelines. The combination of TACE and radiofrequency ablation (RFA) has also been reported as an effective treatment. However, more and more retrospective studies have reported better therapeutic efficacy of hepatic resection than TACE for intermediate HCC. The purpose of this study was to compare the efficacy of hepatic resection versus TACE+RFA for the treatment of intermediate HCC through prospective randomized clinical trial.

Conditions

Interventions

PROCEDURE

Hepatic resection

Anatomical surgical resection of the liver including the tumor. Make sure the resection margin is negative during the process.

PROCEDURE

TACE

TACE will be performed according to the standard procedure of TACE and will be repeated every four months if needed

PROCEDURE

RFA

RFA will be performed 1 week after TACE.

Sponsors & Collaborators

  • Sun Yat-sen University

    collaborator OTHER

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    collaborator OTHER

  • First Affiliated Hospital, Sun Yat-Sen University

    lead OTHER

Principal Investigators

  • Baogang Peng, MD · First Affiliated Hospital of Sun Yat-Sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2018-07-31
Completion
2021-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02616926 on ClinicalTrials.gov